These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9123288)

  • 1. A generic cyclosporine development program.
    Schroeder TJ; Levy R; Pouletty P; First MR
    Transplant Proc; 1997; 29(1-2):1235-8. PubMed ID: 9123288
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients.
    Cooney GF; Lum BL; Meligeni JA; Dunn SP
    Transplant Proc; 1996 Aug; 28(4):2270-2. PubMed ID: 8769222
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic comparison of two cyclosporine A formulations, SangCya (Sang-35) and Neoral, in stable adult liver transplant recipients.
    Fisher RA; Pan SH; Rossi SJ; Schroeder TJ; Irish WD; Canafax DM; Lopez RR
    Transplant Proc; 1999; 31(1-2):394-5. PubMed ID: 10083157
    [No Abstract]   [Full Text] [Related]  

  • 4. Relative bioavailability of Neoral versus Sandimmune in the presence of a P450IIIA and P-glycoprotein inhibitor.
    Choc MG; Mueller EA; Robinson WT; Kumle A; Smith HT; Charnick SB
    Transplant Proc; 1998 Aug; 30(5):1664-5. PubMed ID: 9723234
    [No Abstract]   [Full Text] [Related]  

  • 5. Lessons from the Neoral Global Database.
    Helderman JH
    Transplant Proc; 1998 Aug; 30(5):1721-2. PubMed ID: 9723255
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of conversion from Sandimmune to Neoral on glomerular filtration rate in stable renal transplant recipients.
    Steinmuller D; Dougherty J; Coutee J; Surek D; Swies G; Lewis R
    Transplant Proc; 1997; 29(1-2):298-9. PubMed ID: 9123005
    [No Abstract]   [Full Text] [Related]  

  • 7. Changing stable heart transplant recipients from Sandimmune to Neoral.
    Dalrymple-Hay M; Meara M; Reynolds L; Backhouse L; Wright D; Holt D; Johnston A; Madden B; Murday A
    Transplant Proc; 1996 Aug; 28(4):2285-6. PubMed ID: 8769227
    [No Abstract]   [Full Text] [Related]  

  • 8. Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application?
    Haller GW; Winkler M; Bechstein WO; Oldhafer KJ; Ringe B; Maibücher A; Färber L; Pichlmayr R; Neuhaus P
    Transplant Proc; 1996 Aug; 28(4):2239-40. PubMed ID: 8769211
    [No Abstract]   [Full Text] [Related]  

  • 9. Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption.
    Chapman JR; O'Connell PJ; Bovington KJ; Allen RD
    Transplant Proc; 1996 Aug; 28(4):2293-5. PubMed ID: 8769229
    [No Abstract]   [Full Text] [Related]  

  • 10. Experience with new cyclosporine formulations: Consupren and Neoral in renal transplant patients.
    Barbari A; Stephan A; Kamel G; Kilany H; Masri MA
    Transplant Proc; 1997 Nov; 29(7):2941-4. PubMed ID: 9365622
    [No Abstract]   [Full Text] [Related]  

  • 11. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a Neoral-equivalent cyclosporine formulation, using a dose-adjusted method.
    First MR; Weiskittel P; Shah M; Peddi VR; Canafax D; Schroeder TJ
    Transplant Proc; 1998 Dec; 30(8):3955-7. PubMed ID: 9865260
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus with Sandimmune and Sandimmune Neoral.
    Serafinowicz A; Gaciong Z; Baçzkowska T; Durlik M; Lao M
    Transplant Proc; 1996 Dec; 28(6):3140-1. PubMed ID: 8962217
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year.
    Cooney GF; Jeevanandam V; Choudhury S; Feutren G; Mueller EA; Eisen HJ
    Transplant Proc; 1998 Aug; 30(5):1892-4. PubMed ID: 9723323
    [No Abstract]   [Full Text] [Related]  

  • 14. Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM in renal transplant recipients.
    Lee KL; Lee KT; Chung HM; Lin YP
    Transplant Proc; 1998 Nov; 30(7):3526-9. PubMed ID: 9838545
    [No Abstract]   [Full Text] [Related]  

  • 15. Conversion from Sandimmune to Neoral in stable heart transplant recipients.
    Pethig K; Ruhparwar A; Korn A; Christians U; Wahlers T
    Transplant Proc; 1996 Aug; 28(4):2287-9. PubMed ID: 8769228
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetic studies of oral and intravenous cyclosporine in prekidney transplant patient.
    Wacke R; Bast R; Rohde B; Prall F; Seiter H; Drewelow B
    Transplant Proc; 1998 Aug; 30(5):1663. PubMed ID: 9723233
    [No Abstract]   [Full Text] [Related]  

  • 17. Change of conventional cyclosporine to neoral cyclosporine formulation in long-term liver transplant recipients.
    Diliz HS; Olivera MA; Kershenobich D; Mercado MA; Orozco H
    Transplant Proc; 1996 Dec; 28(6):3348-50. PubMed ID: 8962302
    [No Abstract]   [Full Text] [Related]  

  • 18. Conversion from standard cyclosporine to Neoral in lung transplant recipients.
    Kesten S; Scavuzzo M; Laurin L; Tan A; Chaparro C
    Transplant Proc; 1998 Aug; 30(5):1895-7. PubMed ID: 9723324
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
    Vathsala A; Lee WT; Jacob E; Woo KT
    Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
    [No Abstract]   [Full Text] [Related]  

  • 20. Differences in bioavailability between oral cyclosporine formulations in maintenance renal transplant patients.
    Curtis JJ; Barbeito R; Pirsch J; Lewis RM; Van Buren DH; Choudhury S
    Am J Kidney Dis; 1999 Nov; 34(5):869-74. PubMed ID: 10561143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.